GlaxoSmithKline PLC (GSK) Shares Sold by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. trimmed its holdings in GlaxoSmithKline PLC (NYSE:GSK) by 8.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 102,291 shares of the pharmaceutical company’s stock after selling 9,514 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in GlaxoSmithKline PLC were worth $4,153,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Proficio Capital Partners LLC lifted its holdings in GlaxoSmithKline PLC by 16.1% in the 2nd quarter. Proficio Capital Partners LLC now owns 3,301 shares of the pharmaceutical company’s stock valued at $135,000 after acquiring an additional 457 shares during the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its holdings in GlaxoSmithKline PLC by 1.9% during the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock worth $137,000 after buying an additional 64 shares during the period. FTB Advisors Inc. raised its holdings in GlaxoSmithKline PLC by 16.9% during the 2nd quarter. FTB Advisors Inc. now owns 3,735 shares of the pharmaceutical company’s stock worth $146,000 after buying an additional 539 shares during the period. Quadrant Capital Group LLC raised its holdings in GlaxoSmithKline PLC by 3.5% during the 2nd quarter. Quadrant Capital Group LLC now owns 4,345 shares of the pharmaceutical company’s stock worth $162,000 after buying an additional 148 shares during the period. Finally, Parallel Advisors LLC raised its holdings in GlaxoSmithKline PLC by 93.4% during the 2nd quarter. Parallel Advisors LLC now owns 4,048 shares of the pharmaceutical company’s stock worth $164,000 after buying an additional 1,955 shares during the period. 9.32% of the stock is owned by institutional investors.

GlaxoSmithKline PLC (NYSE GSK) traded down $0.18 on Friday, hitting $35.01. The stock had a trading volume of 796,282 shares, compared to its average volume of 3,443,574. GlaxoSmithKline PLC has a 12 month low of $34.72 and a 12 month high of $44.53. The company has a quick ratio of 0.44, a current ratio of 0.64 and a debt-to-equity ratio of 2.96. The company has a market capitalization of $84,930.00, a PE ratio of 12.37, a price-to-earnings-growth ratio of 1.93 and a beta of 1.00.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 11th. Stockholders of record on Friday, November 10th will be given a $0.5037 dividend. This represents a $2.01 annualized dividend and a dividend yield of 5.75%. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.49. The ex-dividend date of this dividend is Thursday, November 9th. GlaxoSmithKline PLC’s dividend payout ratio is currently 159.20%.

In other GlaxoSmithKline PLC news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of GlaxoSmithKline PLC stock in a transaction dated Monday, November 6th. The stock was bought at an average cost of $14.00 per share, with a total value of $5,999,994.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 10.00% of the stock is currently owned by corporate insiders.

WARNING: “GlaxoSmithKline PLC (GSK) Shares Sold by Cambridge Investment Research Advisors Inc.” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://ledgergazette.com/2017/11/17/glaxosmithkline-plc-gsk-shares-sold-by-cambridge-investment-research-advisors-inc.html.

Several analysts have issued reports on the company. Investec downgraded GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Monday, November 6th. TheStreet upgraded GlaxoSmithKline PLC from a “c+” rating to a “b” rating in a report on Wednesday, October 25th. Bank of America Corporation downgraded GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a report on Thursday, October 26th. Zacks Investment Research downgraded GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. Finally, J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Tuesday, October 24th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have assigned a buy rating to the company. GlaxoSmithKline PLC presently has a consensus rating of “Hold” and a consensus price target of $44.33.

GlaxoSmithKline PLC Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply